Werewolf Therapeutics, Inc.
HOWL
$0.7998
-$0.0702-8.07%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -92.95% | -90.55% | -86.84% | -62.57% | -22.26% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -92.95% | -90.55% | -86.84% | -62.57% | -22.26% |
| Cost of Revenue | 33.86% | 34.16% | 3.13% | -5.29% | -24.17% |
| Gross Profit | -123.32% | -165.31% | -122.08% | -57.51% | 25.47% |
| SG&A Expenses | 2.78% | 8.09% | 8.16% | 6.17% | 1.75% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 22.55% | 24.87% | 4.74% | -1.73% | -16.42% |
| Operating Income | -63.78% | -81.70% | -62.59% | -32.56% | 14.12% |
| Income Before Tax | -74.15% | -88.70% | -66.56% | -31.20% | 17.58% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -74.15% | -88.70% | -66.56% | -31.20% | 17.58% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -74.15% | -88.70% | -66.56% | -31.20% | 17.58% |
| EBIT | -63.78% | -81.70% | -62.59% | -32.56% | 14.12% |
| EBITDA | -66.47% | -85.29% | -65.07% | -33.51% | 15.23% |
| EPS Basic | -50.02% | -55.05% | -34.88% | -5.38% | 34.32% |
| Normalized Basic EPS | -48.89% | -53.86% | -33.75% | -4.38% | 34.33% |
| EPS Diluted | -52.68% | -57.83% | -37.51% | -7.66% | 34.32% |
| Normalized Diluted EPS | -48.47% | -53.42% | -33.33% | -4.02% | 34.33% |
| Average Basic Shares Outstanding | 18.17% | 21.57% | 20.97% | 20.26% | 21.65% |
| Average Diluted Shares Outstanding | 18.52% | 21.93% | 21.35% | 20.66% | 21.65% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |